JUJoseph M. Unger

Joseph M. Unger

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Joseph M. Unger has a total of 421 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • No Evidence of Post-finasteride Syndrome in 267,983 Person-years Follow-up in the Prostate Cancer Prevention Trial

    by Cathee Till, Catherine M. Tangen, Phyllis Goodman, Joseph M. Unger, Ian M. Thompson

  • Open Access

    Comparison of five definitions of meaningful change on patient-reported outcomes in four SWOG clinical trials

    by Salene M. W. Jones, Cathee Till, Joseph M. Unger, Dawn L. Hershman, N. Lynn Henry, Donna L. Berry, Sapna Patel, Evan Hall

    Purpose: The minimally important difference (MID) represents how much change on a patient-reported outcome (PRO) is considered meaningful for defining a patient as improving or worsening. MIDs can be based on a statistical distribution or anchored to another PRO. This study used four SWOG clinical trials with treatments of known toxicities and positive quality of life (QOL) results as a silver standard to compare different MID definitions. Methods: Two breast cancer trials compared true acupuncture (S1200) to sham acupuncture and waitlist control or duloxetine (S1202) to placebo to improve pain. S9346 compared continuous versus intermittent androgen deprivation therapy in metastatic prostate cancer. S1404 compared pembrolizumab with physician’s choice of interferon or ipilimumab in melanoma. Four MID distribution definitions (30% change, 50% change, half a standard deviation (0.5SD), reliable change index (RCI)) and one MID prospective anchor-based definition were compared. Chi-square statistics for intervention effect compared different definitions of MID. Results: In S1200, the 0.5SD and RCI performed the best with the anchor-based method also performing well. In S1202, the anchor method, 0.5SD and 50% change performed well. For S9346, the anchor method performed well in physical function comparisons. For S1404, RCI and 30% change performed well for worsening QOL. Across all comparisons, 0.5SD had the highest mean chi-square values for worsening symptoms and RCI had the highest mean chi-square values for improvement. Conclusion: Results suggest that some distribution-based MID methods may be sensitive to change for symptom and QOL PROs. Anchor-based methods may be the most sensitive for function PROs.

  • Psychosocial Predictors of Shared Decision Making Among US Cancer Survivors

    by Joseph M. Unger

    PURPOSE: Cancer survivors, who have unique health care needs, are projected to number nearly 19 million by 2025, over 5% of the US population. Shared decision making (SDM) between patients and providers is vital for patient-centered care. This study evaluated whether demographic, socioeconomic, behavioral, geographic, health, health information, and psychosocial factors predict the risk of cancer survivors not engaging in SDM. METHODS: Data from the Health Information National Trends Survey (HINTS) from 2012 to 2024 were used. Participants included adults diagnosed with cancer within the past 20 years who had one or more health care visits in the past year. SDM was measured on a four-point scale by a question about involvement in health care decisions, with dichotomization (always v usually/sometimes/never) aligned with Healthy People 2030 objectives. Forty-two variables were analyzed, and a risk prediction model was developed using 60% of the participants and validated with the remaining 40%. RESULTS: The study included 3,622 participants, predominantly older than 65 years (61.5%), with 54.8% being women and 12.9% Black. A model with four variables (distrust of health care providers, distrust of family, anxiety/depression, and fair/poor perceived health) was associated with lower SDM engagement in the training set and was confirmed in the validation set. For each increase in the quartile level of adverse risks, there was a 23% reduction in the odds of SDM. The odds of experiencing SDM were 56% lower for those with 3-4 risk factors than for those with 0 risk factors. CONCLUSION: These findings suggest that screening for psychosocial vulnerability may help identify cancer survivors who could benefit from targeted strategies to support SDM in clinical care.


  • Open Access

    Reporting of Rurality, Deprivation, and Socioeconomic Characteristics in Cancer Clinical Trials

    by Joseph M. Unger

    Importance: The composition of clinical trial populations influences the interpretation and generalizability of cancer trial results. The extent to which geographic and socioeconomic characteristics are reported in primary cancer clinical trial publications is unknown. Objective: To evaluate the frequency and temporal trends in reporting of geographic, socioeconomic, and demographic characteristics in primary publications of US-based randomized cancer clinical trials. Design, Setting, and Participants: This systematic review included US-based randomized phase II or III cancer treatment trials published in high-impact peer-reviewed journals from 2020 to 2025. Using prespecified search strategies and eligibility criteria, primary trial reports were identified. Data were abstracted on reporting of rurality, area-level deprivation, insurance status, income, education, age, sex, race, and ethnicity. Main Outcomes and Measures: Overall prevalence and temporal trends in reporting of geographic, socioeconomic, and demographic characteristics. Results: Among 6681 reviewed trials, 441 met inclusion criteria. Reporting of age and sex was nearly universal. Reporting of race and ethnicity was common, with 365 trials (82.8%) reporting more than 1 category. The most frequently reported race variables were White (356 [80.7%]), Asian (330 [74.8%]), and Black (320 [72.6%]); Hispanic ethnicity was reported in 140 trials (31.8%). Reporting of any race or ethnicity increased from 62.3% (38 of 62) in 2020 to 93.9% (77 of 82) in 2025. In contrast, no trials reported rurality, income, or area deprivation; 2 reported education, and 1 reported insurance. Conclusions: In this systematic review of 441 US-based randomized cancer clinical trials, geographic and socioeconomic characteristics were rarely reported despite increasing attention to social determinants of health. Limited reporting of these characteristics may constrain assessment of trial generalizability and interpretation across diverse populations and care settings.

  • Composition of Health Care Contact Days and Mortality Prediction Among Older Adult Clinical Trial Participants

    by Arjun Gupta, Cathee Till, Michael L. LeBlanc, Dawn L. Hershman, Joseph M. Unger

    PURPOSE: Contact days exceeding trial protocol–mandated care may represent adverse clinical events and portend worse outcomes. Identifying patients at risk of poor outcomes could enable clinical teams to intervene early and support patients' needs. MATERIALS AND METHODS: We linked data from 6 SWOG trials to Medicare claims. We calculated contact days (days with ambulatory, emergency department, inpatient, or facility-based care) and their composition using protocol calendars. Total contact days were delineated as protocol-mandated (planned) ambulatory or unplanned (including unplanned ambulatory v unplanned inpatient). Cox frailty landmark regression analysis was used in a random 60% training set to identify the optimal threshold (percentile) and landmark (months) for contact-day measures as the predictor based on the chi-square statistic. Candidate predictors were tested in the remaining 40% sample. RESULTS: We included 1,429 patients (median age, 71 years, 7.6% Black, 21.4% female). In the first 3 months, among 15,301 contact days in the training set (6.4 contact days per person per month; 21.2% of total days), 4,102 (26.8%) were protocol-mandated ambulatory, and 11,199 (73.2%) were unplanned (including 7,328 [47.9%] ambulatory and 3,871 [25.3%] inpatient). The 2-month follow-up time at the 75th percentile threshold was the optimal model in the training set. In the test set, unplanned contact days, especially unplanned inpatient contact days, were associated with subsequent survival (≥1 unplanned inpatient contact days, adjusted hazard ratio, 1.25 [1.02-1.52], P = .014). CONCLUSION: One in five trial follow-up days was a health care contact day, of which the majority were unplanned ambulatory contact days. Meaningfully decreasing contact-day burdens will require addressing uncoordinated unplanned ambulatory contact days. The low threshold (≥1 in the first 2 months) of unplanned inpatient days in predicting mortality highlights the adverse impact of any acute care use on survival.


  • Open Access

    Policy stringency during the COVID-19 pandemic and healthcare services utilization in China: An interrupted time-series analysis

    by Hong Xiao, Guannan Bai, Fang Liu, Yuechong Cui, Joseph M. Unger

    Background: The COVID-19 pandemic has profoundly impacted healthcare systems worldwide, with China presenting a unique case. As the first country to report COVID-19 cases and the last to lift its stringent Zero-COVID policy, China presents a distinctive context for understanding the long-term effects of the pandemic on healthcare utilization. This study provides a comprehensive analysis of healthcare utilization trends in China over more than four years of the pandemic, focusing on how different phases, including the Zero-COVID policy and its cessation. Methods and findings: We conducted an interrupted time-series analysis of monthly healthcare utilization data from January 2015 to April 2024, including outpatient visits and inpatient discharges, across Mainland China, controlling for underlying secular trends and patterns. Hospital-based healthcare utilization data were sourced from the National Health Commission of China, and daily Policy Stringency Indices (higher values indicating stricter control policies) were obtained from Oxford’s COVID-19 Government Response Tracker. We modeled changes in healthcare utilization using negative binomial regression, comparing actual outcomes with counterfactual estimates based on pre-COVID trends. We assessed healthcare utilization during key pandemic phases, including the post-Zero-COVID period. Healthcare utilization in China experienced substantial declines during the pandemic, with an estimated reduction of 1.21 billion (7%) outpatient visits and 140.9 million (13%) inpatient discharges compared to expected levels from January 2020 to April 2024. The most pronounced declines occurred during the initial pandemic waves and coincided with periods of stringent Zero-COVID measures. Negative associations between the Policy Stringency Index and healthcare utilizations were observed. Before the lifting of the Zero-COVID policy, a 10-point increase in the Policy Stringency Index was associated with a 7.2 percentage point decrease in outpatient visits and a 6.2 percentage point decrease in hospitalizations. Although healthcare utilization gradually rebounded following the cessation of the Zero-COVID policy, as of April 2024, utilization remained below expected levels in 20 (65%) of the 31 regions for outpatient visits and in 23 (74%) for inpatient discharges. Regional disparities were evident, with more developed areas, such as Shanghai and Beijing, experiencing the largest absolute reductions after adjusting for population size. In Shanghai, outpatient visits declined by 4,997 and hospitalizations by 241 per 1,000 people. In contrast, the largest relative reductions occurred in less developed regions, where outpatient visits dropped by 16% in Guizhou and hospitalizations declined by 27% in Shanxi. Use of aggregated routine health system data limited individual-level analyses, assessment of care quality, and disentangling of causal pathways. Conclusions: The COVID-19 pandemic and Zero-COVID policies were associated with substantial and enduring disruptions to healthcare utilization in China, characterized by slow recovery and regional disparities in access. These findings underscore the importance of strengthening healthcare systems to enhance resilience and better balance public health interventions with the maintenance of essential healthcare services in anticipation of future public health crises. Continued targeted efforts are needed to address the delayed recovery, particularly in regions with already strained healthcare infrastructure, and to ensure equitable healthcare access across the country.


  • Top Cited Papers

    Three-Year Follow-Up of Nivolumab-AVD Versus Brentuximab Vedotin–AVD in Adolescents With Advanced-Stage Classic Hodgkin Lymphoma on S1826

    by Sharon M. Castellino, Hongli Li, Alex F. Herrera, Michael LeBlanc, Susan K. Parsons, Joseph M. Unger, Angela Punnett, David Hodgson, Frank G. Keller, Richard A. Drachtman, et al.

    We present a subset analysis on the adolescent cohort of the S1826 randomized phase three trial, comparing nivolumab, doxorubicin, vinblastine, dacarbazine (N-AVD) to brentuximab vedotin-AVD (BV-AVD) in newly diagnosed advanced-stage (AS, stages III and IV) classic Hodgkin lymphoma (cHL). Among 994 patients enrolled, 24% (n = 240) were age 12-17 years. The 3-year progression-free survival (PFS) was significantly higher in the N-AVD group (93% [95% CI, 87 to 96]) compared with the BV-AVD group (82% [95% CI, 73 to 88]; hazard ratio, 0.37 [95% CI, 0.17 to 0.80]). One N-AVD and two BV-AVD patients received protocol-specified residual site radiotherapy (RT). Rates of febrile neutropenia and sepsis were low in both groups. Severe immune-related adverse events were infrequent, although thyroid dysfunction was seen in 7% with N-AVD. Sensory neuropathy (grade ≥2) was more frequent with BV-AVD (14% v 7%) by clinician report. Although premature discontinuation of therapy was reported in 12 N-AVD patients and four BV-AVD patients, no PFS events were noted in the N-AVD group. Patient-reported outcomes indicated less toxicity with N-AVD. N-AVD demonstrated high 3-year PFS in adolescents with AS cHL, with minimal RT use. S1826 exemplifies the benefits of harmonized clinical trial protocols, resulting in timely access to novel agents for adolescents.


  • Open Access

    Disparities in clinical trial participation among older adult Medicare beneficiaries with hematologic malignancies from 2006 to 2019: A SEER–Medicare analysis

    by Inna Y. Gong, Mark J. Soto, Bahar Rafinejad‐Farahani, Joseph M. Unger, Rena M. Conti, Carmen E. Guerra, Amit Oza, Meredith Rosenthal, Danielle Rodin

    Background: Clinical trials (CTs) are essential for expanding treatment options across hematologic malignancies (HM) and providing access to novel treatments. However, older adults with HM are often underrepresented in CTs, and a national‐level evaluation of factors influencing their participation is lacking. Methods: The authors conducted a retrospective cohort study using the Surveillance, Epidemiology, and End Results (SEER)‐Medicare database, identifying patients ≥66 years old diagnosed with HM between 2006 and 2018 (follow‐up to December 2019). CT participation was defined by Medicare claims for CT services. Cumulative incidence and Fine‐Gray models were used to estimate participation rates and adjusted hazard ratios (aHRs) assessed the association between participation and sociodemographic factors. Results: The cohort ( n = 53,919) was 50% female, median age 78 years old, and 86% White. Cumulative incidence of CT participation was low at 2.7% at 1 year after diagnosis, increasing to 4.3% at 5 years. After adjustment for the competing risk of death, significantly lower CT participation was observed for older age (vs. 66–69 years: aHR for 70–74 years, 0.79 [95% CI, 0.71–0.88]; aHR for 75–79 years, 0.63 [95% CI, 0.56–0.70]; aHR for 80–84 years, 0.41 [95% CI, 0.36–0.46]; aHR for ≥85 years, 0.21 [95% CI, 0.18–0.24]), female sex (aHR, 0.79 [95% CI, 0.73–0.86]), Black race (aHR, 0.73 [95% CI, 0.59–0.90]), certain comorbidities (aHR for pulmonary disease, 0.76 [95% CI, 0.68–0.85]; aHR for renal disease, 0.67 [95% CI, 0.59–0.76]), dual Medicare–Medicaid eligibility (aHR, 0.66 [95% CI, 0.56–0.77]), and distance to National Cancer Institute centers from the patient’s ZIP code (aHR for ≥250 miles, 0.64 [95% CI, 0.48–0.86]). Conclusions: These results highlight the need for targeted interventions, such as CT navigator programs and decentralized trials, to increase older adult participation in HM CTs.


  • Development and validation of a risk prediction model for acute care use among older advanced cancer patients on clinical trials

    by Dawn L Hershman, Cathee Till, Michael LeBlanc, Scott Ramsey, Joseph M Unger

    Background: Patients with advanced cancer are at risk for unplanned emergency department (ED) visits and hospital stays. The purpose was to develop and validate a risk prediction model to identify patients at the highest risk for acute care use. Methods: We identified advanced cancer patients aged 65 years and older treated on SWOG trials from 1999 to 2014 using data linked to Medicare claims. The primary outcome was acute care use (ED visits or hospital stays). A 60% random sample training set was used to identify candidate variables. An adverse risk model was built by summing adverse factors and creating high- vs low-risk groups by splitting at the median. This risk model was tested in the 40% validation set. Results: Among 1397 patients from 6 trials, 839 composed the training set. The proportion of patients with at least 1 hospital stay or ED visit was 67.5%. Adverse risk factors were performance status (0 vs ≥1), coronary artery disease, hypertension, and liver disease. Patients with at least 2 factors (high risk; 57.3%) vs 0/1 risk factor (low risk; 42.7%) were more likely to experience acute care (79.6% vs 51.1%, respectively), corresponding to a more than threefold increase in odds ratio (OR = 3.38, 95% confidence interval = 2.48 to 4.62). Results were similar in the test set, indicating successful validation. Among all patients, quartile-level proportions were 48.9% for zero risk factors vs 84.0% for 3/4 risk factors. The C statistic was 0.703. Conclusions: A limited set of 4 variables predicted a threefold increased risk of acute care use in older patients with advanced cancer. Personalized interventions aimed at preventing acute care use could improve the quality of cancer care.

  • ASCO State of Cancer Care in America Special Report 2025: Access to Cancer Clinical Trials in the United States

    by Erin P. Balogh, Laura A. Levit, Joseph M. Unger, Melissa K. Accordino, David D. Chism, M. Kelsey Kirkwood, Helen M. Parsons, Manali I. Patel, Jeffery M. Peppercorn, Blase N. Polite, et al.

    Improving patient access to cancer clinical trials is a fundamental ASCO priority because clinical cancer research is the essential link transforming biomedical discoveries into meaningful progress in cancer care and patient outcomes. Today's standard of care emerged from yesterday's clinical trials. However, numerous barriers continue to threaten patient access to cancer clinical trials. This Special Report describes the essential role clinical trials play in improving cancer care and patient outcomes, current challenges in the design and conduct of clinical trials, and steps taken by ASCO to make clinical trials more accessible, patient-centered, and embedded within the communities where people live.